84 with placebo) during classroom testing
Novos suit seeks a permanent injunction from the court that would require Lilly to pull misleading comparative advertising campaigns and conduct a corrective advertising campaign. key background Lilly and Novo are chief rivals in the GLP-1 market, but Lilly now captures a greater share of prescriptions, CNN reported in February
You may interpret a low response as needing a higher dose when the real issue is that you are not receiving the full dose you intended
Why this matters for treatment selection If GLP-1 facial aging were purely volume loss, the answer would be filler and the conversation would be over
The Food and Drug Administration (FDA) approved the medication to treat type 2 diabetes but health care providers also prescribe it off-label (uses other than originally intended) for the treatment of obesity or to help with weight management
Christensen M, Vedtofte L, Holst JJ, Vilsboll T, Knop FK